Canada markets open in 4 hours 37 minutes

SNY Jan 2025 45.000 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
1.7500+0.6000 (+52.17%)
As of 09:30AM EDT. Market open.
Full screen
Previous Close1.1500
Open1.7500
Bid1.1500
Ask1.8500
Strike45.00
Expire Date2025-01-17
Day's Range1.7500 - 1.7500
Contract RangeN/A
Volume13
Open Interest385
  • GlobeNewswire

    Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma

    Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma FDA Priority Review granted based on positive results from IMROZ phase 3 study If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care treatment for patients with newly diagnosed transplant-ineligible multiple myeloma Pivotal IMROZ phase 3 study results to be featured during oral presentation at the 2024 American Society of Clinical Oncolog

  • Reuters

    Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million

    A judge in Hawaii on Tuesday ordered Bristol Myers Squibb and Sanofi to pay more than $916 million to the state for failing to warn non-white patients of health risks from its blood thinner Plavix, up from an earlier judgment of $834 million. The ruling from Judge James Ashford, of Hawaii's First Circuit Court, follows a non-jury trial held last fall. It was the second trial in the case, after the state's Supreme Court found that the judge in the first trial that resulted in the $834 million award had made a legal error.

  • Associated Press Finance

    Hawaii court orders drug companies to pay $916 million in Plavix blood thinner lawsuit

    A Hawaii court has ordered the manufacturers and distributors of the blood thinner Plavix to pay the state a combined $916 million after finding the companies failed to disclose the efficacy and safety of the medication, the state attorney general said Tuesday. The judgement was issued against Bristol Myers Squibb Company and three U.S.-based subsidiaries of French pharmaceutical company Sanofi. Bristol Myers Squibb and Sanofi said in a joint statement they disagreed with the penalty and plan to appeal.